Patents by Inventor Klaus Mendla

Klaus Mendla has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20150320739
    Abstract: The invention relates to new pharmaceutical compositions for the treatment of sexual disorders and methods for the preparation thereof. In a preferred embodiment, the instant invention is directed to pharmaceutical combinations comprising flibanserin as one active ingredient in combination with at least one additional active ingredient for the treatment of sexual disorders and methods for the preparation thereof.
    Type: Application
    Filed: March 13, 2015
    Publication date: November 12, 2015
    Inventors: Klaus Mendla, Thomas Friedl, Wolfram Eisenreich, Robert E. Pyke
  • Publication number: 20110105519
    Abstract: The invention relates to new pharmaceutical compositions for the treatment of sexual disorders and methods for the preparation thereof. In a preferred embodiment, the instant invention is directed to pharmaceutical combinations comprising flibanserin as one active ingredient in combination with at least one additional active ingredient for the treatment of sexual disorders and methods for the preparation thereof.
    Type: Application
    Filed: January 10, 2011
    Publication date: May 5, 2011
    Inventors: Klaus Mendla, Thomas Friedl, Wolfram Eisenreich, Robert Pyke
  • Publication number: 20080200498
    Abstract: The invention relates to the use of a monoamine neurotransmitter re-uptake inhibitor comprising a 2,3-disubstituted tropane moiety, or a tautomer, a pharmaceutically acceptable salt, solvate, or physiologically functional derivative thereof for the manufacture of a medicament for the for the treatment of sexual desire disorders.
    Type: Application
    Filed: July 6, 2006
    Publication date: August 21, 2008
    Inventors: Angelo Ceci, Klaus Mendla
  • Publication number: 20080103155
    Abstract: The invention relates to new pharmaceutical compositions for the treatment of sexual disorders and methods for the preparation thereof. In a preferred embodiment, the instant invention is directed to pharmaceutical combinations comprising flibanserin as one active ingredient in combination with at least one additional active ingredient for the treatment of sexual disorders and methods for the preparation thereof.
    Type: Application
    Filed: December 20, 2007
    Publication date: May 1, 2008
    Inventors: Klaus Mendla, Thomas Friedl, Wolfram Eisenreich, Robert Pyke
  • Publication number: 20050245539
    Abstract: The invention relates to new pharmaceutical compositions for the treatment of sexual disorders and methods for the preparation thereof. In a preferred embodiment, the instant invention is directed to pharmaceutical combinations comprising flibanserin as one active ingredient in combination with at least one additional active ingredient for the treatment of sexual disorders and methods for the preparation thereof.
    Type: Application
    Filed: April 20, 2005
    Publication date: November 3, 2005
    Applicants: Boehringer Ingelheim International GmbH, Boehringer Ingelheim Pharmaceuticals, Inc.
    Inventors: Klaus Mendla, Thomas Friedl, Wolfram Eisenreich, Robert Pyke
  • Publication number: 20040122068
    Abstract: The invention relates to the use of pramipexole and the pharmacologically acceptable acid addition salts thereof as well as hydrates and solvates thereof, for preparing a pharmaceutical composition for the prevention and/or treatment of HIV encephalopathy.
    Type: Application
    Filed: December 1, 2003
    Publication date: June 24, 2004
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Ralph Warsinsky, Klaus Mendla, Sandra Fleissner, Lothar Kussmaul
  • Publication number: 20030166696
    Abstract: The invention relates to the use of pramipexole and the pharmacologically acceptable acid addition salts thereof as well as hydrates and solvates thereof, for preparing a pharmaceutical composition for the prevention and/or treatment of HIV encephalopathy.
    Type: Application
    Filed: January 21, 2003
    Publication date: September 4, 2003
    Applicant: Boehringer Ingelheim Pharma GmbH & Co. KG
    Inventors: Ralph Warsinsky, Klaus Mendla, Sandra Fleissner, Lothar Kussmaul
  • Patent number: 6573276
    Abstract: Methods of lowering the levels of A&bgr;40, A&bgr;42 and tau protein in a mammal comprising administering to the mammal an effective amount of talsaclidine, or a physiologically acceptable acid addition salt thereof, and methods of treating diseases associated with the formation of diffuse and senile plaques or A&bgr;40-, A&bgr;42- and tau-containing plaques are disclosed.
    Type: Grant
    Filed: April 30, 2002
    Date of Patent: June 3, 2003
    Assignee: Boehringer Ingelheim Pharma KG
    Inventors: Christoph Hock, Andreas Raschig, Marion Wienrich, Roger Nitsch, Klaus Mendla, Dieter Horst Meier, Klaus Bornemann, Cornelia Dorner-Ciossek
  • Publication number: 20030050221
    Abstract: A method of lowering the levels of A&bgr;40, A&bgr;42, and tau protein in a mammal comprising administering to the mammal an effective amount of talsaclidine or a physiologically acceptable acid addition salt thereof and methods of treating or preventing diseases associated with the formation of diffuse and senile plaques or A&bgr;40-, A&bgr;42- and tau-containing plaques.
    Type: Application
    Filed: April 30, 2002
    Publication date: March 13, 2003
    Inventors: Christoph Hock, Andreas Raschig, Marion Wienrich, Roger Nitsch, Klaus Mendla, Dieter Horst Meier, Klaus Bornemann, Cornelia Dorner-Ciossek
  • Patent number: 6514969
    Abstract: Compounds of general formula (I) wherein: A is —CH2—, —CH2—CH2—, —CH2—CH2—CH2—, —CH2—CH2—CH2—CH2—, —CH2—CO—, —CH2—CH2—CO—, or —CH═CH—CO—; Het is piperidinyl, piperazinyl, or dihydrobenzimidazolonyl; R1 is hydrogen or halogen; R2 is hydrogen, C1-C4-alkyl, CF3, or a phenyl group optionally substituted by halogen, C1-C4-alkyl, or C1-C4-alkyloxy; and R3 is hydrogen, C1-C4-alkyl, HO—C1-C4-alkyl, or C2-C4-alkenyl; or a group selected from phenyl, benzyl, and phenylethyl, each optionally substituted by halogen, CF3, C1-C4-alkyl, or C1-C4-alkyloxy; or a heterocycle selected from among morpholine, piperidine, piperazine, and dihydrobenzimidazolone, the heterocycle either linked directly or via a C1-C4-alkylene bridge, or an optical isomer, enantiomer, tautomer, free base, or pharmacologically acceptable acid addition salt thereof; methods of
    Type: Grant
    Filed: July 24, 2001
    Date of Patent: February 4, 2003
    Assignee: Boehringer Ingelheim Pharma KG
    Inventors: Hans Briem, Klaus Mendla, Helmut Michael Romig, Katja Fechteler, Klaus Fuchs
  • Publication number: 20020042420
    Abstract: Compounds of general formula (I) 1
    Type: Application
    Filed: July 24, 2001
    Publication date: April 11, 2002
    Inventors: Hans Briem, Klaus Mendla, Helmut Michael Romig, Katja Fechteler, Klaus Fuchs